Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Single-Arm, Open Label Study Of Irinotecan In Combination With Temozolomide In Children With Recurrent Or Refractory Medulloblastoma And In Children With Newly Diagnosed High-Grade Glioma.

NCT00404495 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00404495
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00404495 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Single-Arm, Open Label Study Of Irinotecan In Combination With Temozolomide In Children With Recurrent Or Refractory Medulloblastoma And In Children With Newly Diagnosed High-Grade Glioma.
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2007
Completion date
December 31, 2011
Enrollment
83 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

glioma, medulloblastoma